文献速递慢性肾脏病血液净化与透析肾血管病与高血压

肾衰竭合并房颤患者血栓栓塞风险的治療策略

Treatment strategies of the thromboembolic risk in kidney failure patients with atrial fibrillation.
PubMed 文献 · Nephrol Dial Transplant · 2024-01-01

肾衰竭(GFR<15 ml/min/1.73 m²)合并房颤患者血栓栓塞预防策略尚不明确,口服抗凝药(VKA或DOAC)疗效与安全性未被证实,三项RCT因样本量不足未达主要终点;左心耳封堵(LAAC)近期研究显示可减少血透合并房颤患者血栓栓塞事件,强调多学科共同决策。

要点

  • 肾衰竭合并房颤患者血栓栓塞预防缺乏明确指南推荐。
  • VKA和DOAC在此人群中的疗效与安全性均未被证实。
  • LAAC可能减少血透合并房颤患者血栓栓塞事件。

核心结论

  • 肾衰竭合并房颤患者血栓栓塞预防策略尚不明确,需多学科共同决策权衡个体风险与获益。

研究设计与样本

  • 综述总结当前治疗标准并讨论肾衰竭合并房颤患者血栓栓塞风险管理的最新进展。

主要发现

  • 三项比较DOAC与VKA在肾衰竭患者中的RCT因样本量不足未达主要终点。
  • 比较LAAC与OAC在肾衰竭患者中的RCT因招募失败提前终止。
  • 近期前瞻性研究显示血透合并房颤患者接受LAAC较接受或不接受OAC者血栓栓塞事件减少。

临床怎么用

  • 肾衰竭合并房颤患者抗凝决策应与多学科团队及患者共同讨论个体风险与获益。

局限性

  • 现有RCT因样本量不足或招募失败未能提供充分证据。
  • 肾衰竭合并房颤患者血栓栓塞预防缺乏明确指南推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The incidence and prevalence of atrial fibrillation (AF) in patients affected by kidney failure, i.e. glomerular filtration rate <15 ml/min/1.73 m2, is high and probably underestimated. Numerous uncertainties remain regarding how to prevent thromboembolic events in this population because both cardiology and nephrology guidelines do not provide clear recommendations. The efficacy and safety of oral anticoagulant therapy (OAC) in preventing thromboembolism in patients with kidney failure and AF has not been demonstrated for either vitamin K antagonists (VKAs) or direct anticoagulants (DOACs). Moreover, it remains unclear which is more effective and safer, because estimated creatinine clearance <25-30 ml/min was an exclusion criterion in the randomized controlled trials (RCTs). Three RCTs comparing DOACs and VKAs in kidney failure failed to reach the primary endpoint, as they were underpowered. The left atrial appendage is the main source of thromboembolism in the presence of AF. Left atrial appendage closure (LAAC) has recently been proposed as an alternative to OAC. RCTs comparing the efficacy and safety of LAAC versus OAC in kidney failure were terminated prematurely due to recruitment failure. A recent prospective study showed a reduction in thromboembolic events in haemodialysis patients with AF and undergoing LAAC compared with patients taking or not taking OAC. We review current treatment standards and discuss recent developments in managing the thromboembolic risk in kidney failure patients with AF. The importance of shared decision-making with the multidisciplinary team and the patient to consider individual risks and benefits of each treatment option is underlined.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Genovesi S, Camm AJ, Covic A, et al. Treatment strategies of the thromboembolic risk in kidney failure patients with atrial fibrillation. Nephrol Dial Transplant. 2024. PMID: 38816212. doi:10.1093/ndt/gfae121

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。